flow trial semaglutide nejm 🚨#FLOW: The most anticipated of the year now published in @NEJM with #ERA24 1.0mg once weekly disease modifying with kidney, CV, & mortality benefits in people w T2D+CKD Semaglutide in Patients with Heart

Its main effects include: Increasing lipolysis (fat breakdown) Reducing lipogenesis (fat storage) Improving fat metabolism signaling Doing so without affecting muscle, bone, or glucose regulation Importantly: It does not stimulate growth hormone release It does not rely on pituitary feedback loops It does not act on central appetite pathways This is why it has such a clean safety profile

762 Noh, S

One of its key physiological roles involves the modulation of postprandial glycemic fluctuations, primarily achieved through stimulating insulin release and concurrently diminishing glucagon output

Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance